Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue - Wikidata - awgldk - TriplyDB

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue

http://www.wikidata.org/entity/Q35017035

about

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma Early events during neoplastic progression in Barrett's esophagus Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk Molecular biology of Barrett's adenocarcinoma.Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies.Clinical implications and utility of field cancerization Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.p16 mutation spectrum in the premalignant condition Barrett's esophagus.Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Evidence for DNA damage checkpoint activation in barrett esophagus History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.Barrett's esophagus and cancer risk: how research advances can impact clinical practice.Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma.The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.Clonal selection and persistence in dysplastic Barrett's esophagus and intramucosal cancers after failed radiofrequency ablation.Deletion at fragile sites is a common and early event in Barrett's esophagus.Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus.Paired exome analysis of Barrett's esophagus and adenocarcinoma.Meta-analysis of biomarkers predicting risk of malignant progression in Barrett's oesophagus.Preneoplastic lesion growth driven by the death of adjacent normal stem cells.Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.Surrogate Markers: Lessons from the Next Gen?Impact of tumor progression on cancer incidence curves Esophageal adenocarcinoma arising in Barrett esophagus Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer.In vivo cancer biomarkers of esophageal neoplasia Field cancerization in the GI tract.Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.Ablation of Barrett's oesophagus: towards improved outcomes for oesophageal cancer?Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development.A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.The Complex, Clonal, and Controversial Nature of Barrett's Esophagus.Genomics of Esophageal Cancer and Biomarkers for Early Detection.

P2860

Q21563424-A2234DD7-8E66-4DFA-861C-02B585C68B85 Q26825349-A4C0246E-F217-4136-9B32-51C51DEDE1D1 Q28244692-2DAE84E9-5662-4725-892C-F1F7877ABC0B Q30327935-845F5904-D5EC-4EC3-B4D5-2404D7BC0408 Q32090180-C365B4D8-8D13-46D9-A425-7C36F3E8AEA2 Q33278836-1378A726-A6FD-4B5F-981B-87DF777FA0E5 Q33321476-0B3BC316-CCFC-45F6-8CF2-57A702BBED4E Q33388259-B5811EF2-391B-4BDE-9177-22281356B23A Q33449893-0E69C25D-FBD1-4A77-A102-9CB72638783C Q33600507-2994360A-66C0-4863-8AB1-89A29760E89E Q33655360-20BCC5B8-87B8-4CEA-94D5-55FE090F0F82 Q33786336-5B8A4EEB-0023-4463-A5FD-A40C6453E86A Q33959620-C729AF84-4CE9-4EE2-A114-B462E01509D4 Q33987679-F0FFA5DF-7C05-4AA3-BF50-CE9A0DBE0D8A Q34586242-3842BE07-CDA4-465B-B5A8-DADE3CBA1071 Q34670849-9E8268DA-D4D6-4572-9177-9515F32E0D7F Q34703662-07BFF24F-F3FE-4C9D-B469-5018EBB6CCBD Q34818554-A117883C-A85C-4CE3-BEA4-4F7B56379147 Q34933881-8A3DA170-7405-47C2-9BA3-200B797D8FBC Q35002032-17FDBC73-E0DC-423F-8664-A97E83E7CC08 Q35658948-7A614ADB-308E-455D-A91A-898A6424E1B6 Q35666522-C1885103-93EF-4743-BAE0-C3043FCF1A75 Q35925200-B1EAFED9-864D-48C8-8F16-66F73EDB3102 Q35953908-B0F6A54E-87D1-4565-A590-33F4D90F66FE Q36004465-6ABBC2BA-F7E2-4B5B-BD24-1DCC847830A4 Q36308513-89944072-9DB4-42B2-AE7F-43F3FB308D6D Q36937157-375D46AC-FC68-4C25-BF8F-948079DE54F6 Q36983098-4F0C329D-0783-4C76-A3D8-871AC234163E Q37059872-D99DEEBA-A945-42BD-B568-45511CF5BC02 Q37103785-FB9EE860-6ADA-4956-BA08-7703FE51EED4 Q37169303-776BAC92-597A-4B95-A390-750BEF9FF437 Q37240773-E85C8AE0-1EAB-44DD-9015-E5F34F256BB7 Q37363691-1303E084-F073-4C39-A51A-3FD1871541A4 Q37913358-4DC5B2F4-0A03-4EFF-94F8-2726E624F8D8 Q38018063-E779C5C8-E5EF-4EE1-B579-56477B243A79 Q38035457-AF0CB8CC-0403-4899-84C9-C4F401A2BC70 Q38071593-647C6A27-D628-4337-8AFB-3EAB4C150E83 Q38925807-18A3C9AA-CB9C-40B5-B91E-CDD0AD5A1264 Q38940507-41477235-40BA-43FD-859A-6AEADC2621A5 Q38940530-D3197047-A247-45C1-A76E-08FA06FC37A7

P2860

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue

http://www.wikidata.org/entity/Q35017035

description

1999 nî lūn-bûn

@nan

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@ast

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@en

type

label

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@ast

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@en

prefLabel

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@ast

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@en

P1433

Q35017035-795ED524-B763-43F0-81AE-C5F6D845A840

P1476

Q35017035-62BAE838-12B2-4CB7-8CBE-06C5BB34BCCC

P2093

Q35017035-0ECE55E8-1E25-4C7C-8F99-1313C4A941EC

Q35017035-57EA52FA-7CD2-44DE-B845-F6F380B842D1

Q35017035-977A548E-FE69-4DDA-A5BC-1C5F0F3E0603

Q35017035-DA4C9A81-E4D4-42FD-8D94-F1747E4C4E84

Q35017035-DFBBBAB5-0A81-4B04-AA90-7282F695385E

P2860

Q35017035-097A92DA-DBB0-477B-BEF3-A2F62D4F53B9

Q35017035-29134EB9-ADB8-4C88-80FB-86222194B004

Q35017035-35C70426-04F6-4F46-B32A-5F39DF8E2200

Q35017035-3F2E5877-AF4D-4F9C-AD2C-0D9077AADD14

Q35017035-426119FC-2417-4797-85A5-2FF0C8FA1142

Q35017035-444927EB-A9CB-4E8F-A18E-F1EF4F0E5D38

Q35017035-47D04793-C638-4FDE-B990-179378699BC5

Q35017035-4D0468E5-D88C-47A5-8CB0-50A6B1FB2FE1

Q35017035-4D553653-56CD-474B-A24E-C0F641804AEB

Q35017035-53D2F20C-7150-46CD-9A60-EDE641CCD525

P304

Q35017035-BC81F922-5FC6-46B3-B888-1994A8B47CA9

P31

Q35017035-428F43C2-7790-424D-8A1A-BB1DCCA0D261

P356

Q35017035-425FEECF-923B-4717-B21F-A4ECEC40997F

P407

Q35017035-36368C3D-005F-48D9-B4FC-0E37B587429D

P433

Q35017035-A8A958AA-E0B9-47AF-BEF9-46494B4225B4

P478

Q35017035-4AE6986A-AABA-4AFB-B743-47A20D1360CE

P577

Q35017035-27FC848B-B3D2-46B7-BF54-08D87D850AB2

P5875

Q35017035-4EB2AC70-1BE0-4A60-A330-F2D7DA676340

P698

Q35017035-1332C029-CDE2-4EDF-A2BD-3E8F3C7F6D63

P932

Q35017035-81F4524E-647C-4DC5-8B18-341AE0F4E90E

P356

P1433

Journal of the National Cancer Institute

P1476

Clonal expansion and loss of h ...... esophageal (Barrett's) tissue

@en

P2093

B J Reid

http://www.w3.org/2001/XMLSchema#string

C A Sanchez

http://www.w3.org/2001/XMLSchema#string

G M Longton

http://www.w3.org/2001/XMLSchema#string

L J Prevo

http://www.w3.org/2001/XMLSchema#string

P C Galipeau

http://www.w3.org/2001/XMLSchema#string

P2860

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence

Evolution of neoplastic cell lineages in Barrett oesophagus

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

The clonal evolution of tumor cell populations

Longitudinal data analysis for discrete and continuous outcomes

p53: puzzle and paradigm

Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus

Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.

Cell proliferation in three types of Barrett's epithelium.

P304

2087-2095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/91.24.2087

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12700795

http://www.w3.org/2001/XMLSchema#string

P698

10601379

http://www.w3.org/2001/XMLSchema#string

P932

1559996

http://www.w3.org/2001/XMLSchema#string